Apyx Medical (NASDAQ:APYX) Stock Price Up 0.9% – Here’s What Happened

Apyx Medical Corporation (NASDAQ:APYX) shares traded up 0.9% during trading on Friday . The stock traded as high as $3.59 and last traded at $3.49. 26,658 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 46,115 shares. The stock had previously closed at $3.46.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Roth Capital initiated coverage on Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 price target on the stock. Zacks Research raised Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th. Citizens Jmp upgraded shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price target for the company in a research note on Wednesday, November 12th. Finally, Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Apyx Medical Trading Up 0.9%

The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44. The firm has a 50 day simple moving average of $3.76 and a two-hundred day simple moving average of $2.82. The firm has a market capitalization of $133.46 million, a P/E ratio of -9.69 and a beta of 1.53.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $12.00 million. Apyx Medical had a negative net margin of 30.35% and a negative return on equity of 151.01%. Equities research analysts forecast that Apyx Medical Corporation will post -0.68 earnings per share for the current year.

Institutional Trading of Apyx Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC boosted its position in Apyx Medical by 38.7% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 896,736 shares of the company’s stock worth $2,018,000 after purchasing an additional 250,167 shares during the last quarter. Kingsview Wealth Management LLC raised its stake in shares of Apyx Medical by 9.4% during the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock worth $431,000 after purchasing an additional 16,502 shares during the period. Fisher Asset Management LLC purchased a new position in shares of Apyx Medical in the 2nd quarter worth about $34,000. Nantahala Capital Management LLC grew its position in Apyx Medical by 2.5% during the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after buying an additional 80,000 shares during the period. Finally, Osaic Holdings Inc. bought a new position in Apyx Medical during the second quarter valued at about $50,000. 55.33% of the stock is owned by hedge funds and other institutional investors.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.